Terms: = Sarcomas AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR
43 results:
1. Revealing the pharmacological effects of Remodelin against osteosarcoma based on network pharmacology, acRIP-seq and experimental validation.
Gao J; Xu P; Wang F; Zhang W; Min M; Urba R; Fan L
Sci Rep; 2024 Feb; 14(1):3577. PubMed ID: 38347067
[TBL] [Abstract] [Full Text] [Related]
2. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Piha-Paul SA; Xu B; Dumbrava EE; Fu S; Karp DD; Meric-Bernstam F; Hong DS; Rodon JA; Tsimberidou AM; Raghav K; Ajani JA; Conley AP; Mott F; Fan Y; Fan J; Peng P; Wang H; Ni S; Sun C; Qiang X; Levin WJ; Ngo B; Ru QC; Wu F; Javle MM
Oncologist; 2024 Apr; 29(4):e514-e525. PubMed ID: 38297981
[TBL] [Abstract] [Full Text] [Related]
3. Molecular Profile of Intrahepatic Cholangiocarcinoma.
Andraus W; Tustumi F; de Meira Junior JD; Pinheiro RSN; Waisberg DR; Lopes LD; Arantes RM; Rocha Santos V; de Martino RB; Carneiro D'Albuquerque LA
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203635
[TBL] [Abstract] [Full Text] [Related]
4. Receptor tyrosine kinase gene expression profiling of orbital rhabdomyosarcoma unveils MET as a potential biomarker and therapeutic target.
Chauhan S; Sen S; Irshad K; Kashyap S; Pushker N; Meel R; Sharma MC
Hum Cell; 2024 Jan; 37(1):297-309. PubMed ID: 37914903
[TBL] [Abstract] [Full Text] [Related]
5. FGF2 drives osteosarcoma metastasis through activating FGFR1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
6. Targeting the Sequences of Circulating Tumor DNA of Cholangiocarcinomas and Its Applications and Limitations in Clinical Practice.
Kim KH; Yi HS; Lee H; Bae GE; Yeo MK
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108676
[TBL] [Abstract] [Full Text] [Related]
7. Chondrosarcoma with Target-Like Chondrocytes: Update on Molecular Profiling and Specific Morphological Features.
Povýšil C; Hojný J; Kaňa M
Folia Biol (Praha); 2022; 68(3):112-124. PubMed ID: 36689318
[TBL] [Abstract] [Full Text] [Related]
8. 4D-CT as a second line preoperative localization test for the evaluation of primary hyperparathyroidism.
Barranquero AG; Pastor P; Ortega A; Corral S; Gómez Ramírez J; Luengo P; Porrero B; Cabañas LJ
Cir Esp (Engl Ed); 2023 Aug; 101(8):530-537. PubMed ID: 35905870
[TBL] [Abstract] [Full Text] [Related]
9. Gastric carcinosarcoma with fgfr2 amplification under long-term control with pazopanib: a case report and literature review.
Hayashi H; Makiyama A; Okumura N; Yasufuku I; Saigo C; Takeuchi T; Miyazaki T; Tanaka Y; Matsuhashi N; Murase K; Takahashi T; Futamura M; Yoshida K
BMC Gastroenterol; 2022 Jul; 22(1):360. PubMed ID: 35902814
[TBL] [Abstract] [Full Text] [Related]
10. Integrated DNA Copy Number and Expression Profiling Identifies IGF1R as a Prognostic Biomarker in Pediatric Osteosarcoma.
Taylor AM; Sun JM; Yu A; Voicu H; Shen J; Barkauskas DA; Triche TJ; Gastier-Foster JM; Man TK; Lau CC
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887382
[TBL] [Abstract] [Full Text] [Related]
11. FGF7-fgfr2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas.
Milton CI; Selfe J; Aladowicz E; Man SYK; Bernauer C; Missiaglia E; Walters ZS; Gatz SA; Kelsey A; Generali M; Box G; Valenti M; de Haven-Brandon A; Galiwango D; Hayes A; Clarke M; Izquierdo E; Gonzalez De Castro D; Raynaud FI; Kirkin V; Shipley JM
Mol Oncol; 2022 Mar; 16(6):1272-1289. PubMed ID: 34850536
[TBL] [Abstract] [Full Text] [Related]
12. Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation.
Harttrampf AC; da Costa MEM; Renoult A; Daudigeos-Dubus E; Geoerger B
BMC Cancer; 2021 Jul; 21(1):833. PubMed ID: 34281526
[TBL] [Abstract] [Full Text] [Related]
13. ETV4 and ETV5 drive synovial sarcoma through cell cycle and DUX4 embryonic pathway control.
DeSalvo J; Ban Y; Li L; Sun X; Jiang Z; Kerr DA; Khanlari M; Boulina M; Capecchi MR; Partanen JM; Chen L; Kondo T; Ornitz DM; Trent JC; Eid JE
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 33983905
[TBL] [Abstract] [Full Text] [Related]
14. Investigation of anticancer activities of STA-9090 (ganetespib) as a second generation HSP90 inhibitor in Saos-2 osteosarcoma cells.
Özgür A
J Chemother; 2021 Dec; 33(8):554-563. PubMed ID: 33794753
[TBL] [Abstract] [Full Text] [Related]
15. High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies.
Toulmonde M; Lucchesi C; Verbeke S; Crombe A; Adam J; Geneste D; Chaire V; Laroche-Clary A; Perret R; Bertucci F; Bertolo F; Bianchini L; Dadone-Montaudie B; Hembrough T; Sweet S; Kim YJ; Cecchi F; Le Loarer F; Italiano A
EBioMedicine; 2020 Dec; 62():103131. PubMed ID: 33254023
[TBL] [Abstract] [Full Text] [Related]
16. Receptor Tyrosine Kinases in Osteosarcoma: 2019 Update.
Greenfield EM; Collier CD; Getty PJ
Adv Exp Med Biol; 2020; 1258():141-155. PubMed ID: 32767239
[TBL] [Abstract] [Full Text] [Related]
17. BRAF V600E mutation is a potential therapeutic target for a small subset of synovial sarcoma.
Watanabe S; Shimomura A; Kubo T; Sekimizu M; Seo T; Watanabe SI; Kawai A; Yamamoto N; Tamura K; Kohno T; Ichikawa H; Yoshida A
Mod Pathol; 2020 Sep; 33(9):1660-1668. PubMed ID: 32238877
[TBL] [Abstract] [Full Text] [Related]
18. MiR-16-1-3p and miR-16-2-3p possess strong tumor suppressive and antimetastatic properties in osteosarcoma.
Maximov VV; Akkawi R; Khawaled S; Salah Z; Jaber L; Barhoum A; Or O; Galasso M; Kurek KC; Yavin E; Aqeilan RI
Int J Cancer; 2019 Dec; 145(11):3052-3063. PubMed ID: 31018244
[TBL] [Abstract] [Full Text] [Related]
19. Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas.
Liu Y; Weber Z; San Lucas FA; Deshpande A; Jakubek YA; Sulaiman R; Fagerness M; Flier N; Sulaiman J; Davis CM; Fowler J; Starks D; Rojas-Espaillat L; Lazar AJ; Davies GE; Ehli EA; Scheet P
Gynecol Oncol; 2018 Nov; 151(2):243-249. PubMed ID: 30194005
[TBL] [Abstract] [Full Text] [Related]
20. Adaptive Fibrogenic Reprogramming of Osteosarcoma Stem Cells Promotes Metastatic Growth.
Zhang W; Zhao JM; Lin J; Hu CZ; Zhang WB; Yang WL; Zhang J; Zhang JW; Zhu J
Cell Rep; 2018 Jul; 24(5):1266-1277.e5. PubMed ID: 30067981
[TBL] [Abstract] [Full Text] [Related]
[Next]
